Ursodeoxycholic Acid (Ursocol) in Pregnancy
Ursodeoxycholic acid (UDCA) should be offered for treatment of intrahepatic cholestasis of pregnancy (ICP), particularly when serum bile acids exceed 40 μmol/L, at a dose of 10-15 mg/kg/day divided into multiple doses. 1, 2
Diagnosis and Treatment Indication
The diagnosis of ICP requires:
- Serum bile acid levels >10 μmol/L
- Pruritus (typically in second or third trimester)
- Exclusion of other liver diseases 1
UDCA treatment is strongly recommended when bile acids are >40 μmol/L to reduce the risk of spontaneous preterm birth and potentially protect against stillbirth 2.
Dosing Regimen
Use 10-15 mg/kg/day total daily dose 1, which typically translates to:
- Start with 450-1000 mg daily divided into 2-4 doses
- Most studies used 8-10 mg/kg body weight daily 3
- Continue until delivery 2
- Stop at time of delivery and reduce gradually 2-4 weeks postpartum if symptoms persist 2
Important Dosing Consideration
Recent evidence suggests gradual dose escalation may improve neonatal outcomes compared to starting with full dose immediately 4. Consider starting lower and titrating up rather than initiating full dose at diagnosis, though this requires further validation.
Clinical Benefits
Maternal Benefits:
- Modest improvement in pruritus (though effect may be below minimum clinically significant threshold in some patients) 2
- Significant reduction in ALT/AST levels (78.5% and 73.8% reduction respectively) 3
- Reduction in serum bile acids by approximately 60% 3
- Improvement in bilirubin levels 5, 6
Fetal/Neonatal Benefits:
The most recent and highest quality evidence—a 2021 individual participant data meta-analysis of 6,974 women 7—showed:
- When analyzing only randomized controlled trials: UDCA reduced the composite outcome of stillbirth plus preterm birth (aOR 0.60, p=0.016) 7
- Reduced premature births (RR 0.56) 8
- Reduced fetal distress (RR 0.68) 8
- Higher Apgar scores at 5 minutes 8
- Less respiratory distress syndrome (RR 0.33) 8
- Fewer NICU admissions (RR 0.55) 8
- Deliveries closer to term (38.7 vs 37.4 weeks) 3
Critical caveat: The meta-analysis found no significant effect on stillbirth alone when analyzing all studies (aOR 1.04, p=0.95), though this was likely underpowered due to low event rates 7. The protective effect was only evident in the composite outcome when restricting analysis to RCTs.
Safety Profile
UDCA is safe in pregnancy 2, 9:
- Animal studies at 20-100 fold human doses showed no fetal harm 9
- Four women inadvertently exposed in first trimester had no adverse effects 9
- No maternal or neonatal adverse effects reported in clinical trials 5, 6, 3
- Well tolerated with minimal side effects (occasional nausea/emesis) 8
However, the FDA label states the drug "is not recommended for use during pregnancy" 9 because adequate controlled studies in pregnant women are lacking—this represents regulatory caution rather than evidence of harm.
Superiority Over Alternatives
UDCA is superior to cholestyramine 3:
- 66.6% vs 19.0% reduction in pruritus
- More effective reduction in aminotransferases and bile acids
- Better tolerated (cholestyramine has GI side effects)
- Babies delivered closer to term
Monitoring Protocol
- Check serum bile acids (non-fasting) at least weekly as they may continue rising with advancing gestation 2
- Monitor liver function tests weekly 2
- Ensure bile acids, ALT/AST, and bilirubin return to normal within 3 months postpartum; if not, investigate for underlying liver disease 2
Drug Interactions to Avoid
Do not co-administer with 9:
- Cholestyramine or colestipol (reduce UDCA absorption)
- Aluminum-based antacids (interfere with bile acid absorption)
- Estrogens/oral contraceptives (counteract effectiveness by increasing cholesterol secretion)
Delivery Timing Considerations
While UDCA improves outcomes, delivery timing should be based on bile acid levels 2:
- Bile acids >100 μmol/L: Consider delivery from 35 weeks (stillbirth risk rises markedly after this point)
- Bile acids 40-100 μmol/L: Consider induction by 39 weeks
- Continue weekly monitoring regardless of UDCA treatment
Clinical Bottom Line
UDCA is the first-line treatment for ICP and should be offered to all patients with bile acids >40 μmol/L at 10-15 mg/kg/day. While its effect on pruritus is modest, the most recent high-quality evidence from randomized trials demonstrates protection against the composite outcome of stillbirth and preterm birth 7. The drug has an excellent safety profile with no documented fetal harm 2, 9. Despite FDA labeling caution, current international guidelines from both AGA (2024) and EASL (2023) strongly recommend its use based on the balance of benefits versus risks 1, 2.